文献速递真菌感染细菌感染、耐药与抗菌药物

美国9个监测点成人念珠菌血症治疗实践与IDSA指南依从性

Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018.
PubMed 文献 · Clin Infect Dis · 2021-01-01

基于2017-2018年美国9个主动监测点1835例接受抗真菌治疗的成人念珠菌血症患者,68.6%初始使用棘白菌素、29.6%初始使用氟康唑。肝硬化是初始选择棘白菌素的唯一显著相关基础疾病。初始氟康唑治疗者中56.0%培养为非白念珠菌,有药敏结果者中10.6%为氟康唑耐药,提示部分治疗可能不恰当。

要点

  • 68.6%成人念珠菌血症初始用棘白菌素,29.6%初始用氟康唑。
  • 肝硬化与初始选择棘白菌素显著相关(aOR=2.06)。
  • 初始氟康唑者中56.0%为非白念珠菌,10.6%为氟康唑耐药。

核心结论

  • 相当比例念珠菌血症患者初始接受氟康唑治疗,对非白念珠菌或氟康唑耐药株可能不恰当。
  • 应评估未遵循IDSA指南的原因并加强临床医生教育。

研究设计与样本

  • 2017-2018年Emerging Infections Program在美国9个监测点开展基于人群的主动念珠菌血症监测,采用标准化病例定义。
  • 分析1835例接受抗真菌治疗的成人患者,用多因素logistic回归评估初始抗真菌治疗相关因素。

主要发现

  • 1835例中1258例(68.6%)初始用棘白菌素,543例(29.6%)初始用氟康唑。
  • 肝硬化是唯一与初始选择棘白菌素(对比氟康唑)显著相关的基础疾病(aOR=2.06;95%CI 1.29-3.29)。
  • 初始氟康唑者中304例(56.0%)培养为非白念珠菌。
  • 265例初始氟康唑且有氟康唑药敏结果者中,28例(10.6%)为氟康唑耐药株。

关键数值与推荐

  • IDSA于2016年更新指南,推荐棘白菌素优于氟康唑作为成人念珠菌血症一线治疗。
  • 初始氟康唑者中56.0%为非白念珠菌,有药敏结果者中10.6%为氟康唑耐药。

临床怎么用

  • 成人念珠菌血症初始治疗应优先考虑棘白菌素以覆盖非白念珠菌和耐药株。
  • 初始选用氟康唑时应结合菌种鉴定和药敏结果及时评估并调整方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Candidemia is a common opportunistic infection causing substantial morbidity and mortality. Because of an increasing proportion of non-albicans Candida species and rising antifungal drug resistance, the Infectious Diseases Society of America (IDSA) changed treatment guidelines in 2016 to recommend echinocandins over fluconazole as first-line treatment for adults with candidemia. We describe candidemia treatment practices and adherence to the updated guidelines. METHODS: During 2017-2018, the Emerging Infections Program conducted active population-based candidemia surveillance at 9 US sites using a standardized case definition. We assessed factors associated with initial antifungal treatment for the first candidemia case among adults using multivariable logistic regression models. To identify instances of potentially inappropriate treatment, we compared the first antifungal drug received with species and antifungal susceptibility testing (AFST) results from initial blood cultures. RESULTS: Among 1835 patients who received antifungal treatment, 1258 (68.6%) received an echinocandin and 543 (29.6%) received fluconazole as initial treatment. Cirrhosis (adjusted odds ratio = 2.06; 95% confidence interval, 1.29-3.29) was the only underlying medical condition significantly associated with initial receipt of an echinocandin (versus fluconazole). More than one-half (n = 304, 56.0%) of patients initially treated with fluconazole grew a non-albicans species. Among 265 patients initially treated with fluconazole and with fluconazole AFST results, 28 (10.6%) had a fluconazole-resistant isolate. CONCLUSIONS: A substantial proportion of patients with candidemia were initially treated with fluconazole, resulting in potentially inappropriate treatment for those involving non-albicans or fluconazole-resistant species. Reasons for nonadherence to IDSA guidelines should be evaluated, and clinician education is needed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gold JAW, Seagle EE, Nadle J, et al. Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018. Clin Infect Dis. 2021. PMID: 34079987. doi:10.1093/cid/ciab512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。